194 related articles for article (PubMed ID: 27705911)
1. Targeting SALL4 by entinostat in lung cancer.
Yong KJ; Li A; Ou WB; Hong CK; Zhao W; Wang F; Tatetsu H; Yan B; Qi L; Fletcher JA; Yang H; Soo R; Tenen DG; Chai L
Oncotarget; 2016 Nov; 7(46):75425-75440. PubMed ID: 27705911
[TBL] [Abstract][Full Text] [Related]
2. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.
Lee J; Bartholomeusz C; Mansour O; Humphries J; Hortobagyi GN; Ordentlich P; Ueno NT
Breast Cancer Res Treat; 2014 Jul; 146(2):259-72. PubMed ID: 24916181
[TBL] [Abstract][Full Text] [Related]
3. HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2.
Sabnis GJ; Goloubeva OG; Kazi AA; Shah P; Brodie AH
Mol Cancer Ther; 2013 Dec; 12(12):2804-16. PubMed ID: 24092810
[TBL] [Abstract][Full Text] [Related]
4. Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells.
Schech A; Kazi A; Yu S; Shah P; Sabnis G
Mol Cancer Ther; 2015 Aug; 14(8):1848-57. PubMed ID: 26037781
[TBL] [Abstract][Full Text] [Related]
5. Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer.
Tanioka M; Mott KR; Hollern DP; Fan C; Darr DB; Perou CM
Genome Med; 2018 Nov; 10(1):86. PubMed ID: 30497520
[TBL] [Abstract][Full Text] [Related]
6. The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells.
Zhu S; Denman CJ; Cobanoglu ZS; Kiany S; Lau CC; Gottschalk SM; Hughes DP; Kleinerman ES; Lee DA
Pharm Res; 2015 Mar; 32(3):779-92. PubMed ID: 24203492
[TBL] [Abstract][Full Text] [Related]
7. Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
Frys S; Simons Z; Hu Q; Barth MJ; Gu JJ; Mavis C; Skitzki J; Song L; Czuczman MS; Hernandez-Ilizaliturri FJ
Br J Haematol; 2015 May; 169(4):506-19. PubMed ID: 25712263
[TBL] [Abstract][Full Text] [Related]
8. Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis.
Ma Y; Baltezor M; Rajewski L; Crow J; Samuel G; Staggs VS; Chastain KM; Toretsky JA; Weir SJ; Godwin AK
J Mol Med (Berl); 2019 Jul; 97(7):957-972. PubMed ID: 31025088
[TBL] [Abstract][Full Text] [Related]
9. Targeting SALL4 by Entinostat Inhibits the Malignant Phenotype of Gastric Cancer Cells by Reducing EMT Signaling.
DU L; Xie F; Han H; Zhang L
Anticancer Res; 2023 Oct; 43(10):4389-4401. PubMed ID: 37772555
[TBL] [Abstract][Full Text] [Related]
10. The antitumor effects of entinostat in ovarian cancer require adaptive immunity.
Smith HJ; McCaw TR; Londono AI; Katre AA; Meza-Perez S; Yang ES; Forero A; Buchsbaum DJ; Randall TD; Straughn JM; Norian LA; Arend RC
Cancer; 2018 Dec; 124(24):4657-4666. PubMed ID: 30423192
[TBL] [Abstract][Full Text] [Related]
11. New High-Throughput Screening Identifies Compounds That Reduce Viability Specifically in Liver Cancer Cells That Express High Levels of SALL4 by Inhibiting Oxidative Phosphorylation.
Tan JL; Li F; Yeo JZ; Yong KJ; Bassal MA; Ng GH; Lee MY; Leong CY; Tan HK; Wu CS; Liu BH; Chan TH; Tan ZH; Chan YS; Wang S; Lim ZH; Toh TB; Hooi L; Low KN; Ma S; Kong NR; Stein AJ; Wu Y; Thangavelu MT; Suzuki A; Periyasamy G; Asara JM; Dan YY; Bonney GK; Chow EK; Lu GD; Ng HH; Kanagasundaram Y; Ng SB; Tam WL; Tenen DG; Chai L
Gastroenterology; 2019 Dec; 157(6):1615-1629.e17. PubMed ID: 31446059
[TBL] [Abstract][Full Text] [Related]
12. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.
Shen L; Ciesielski M; Ramakrishnan S; Miles KM; Ellis L; Sotomayor P; Shrikant P; Fenstermaker R; Pili R
PLoS One; 2012; 7(1):e30815. PubMed ID: 22303460
[TBL] [Abstract][Full Text] [Related]
13. Entinostat (SNDX-275) for the treatment of non-small cell lung cancer.
Ruiz R; Raez LE; Rolfo C
Expert Opin Investig Drugs; 2015; 24(8):1101-9. PubMed ID: 26098363
[TBL] [Abstract][Full Text] [Related]
14. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
15. Targeting transcription factor SALL4 in acute myeloid leukemia by interrupting its interaction with an epigenetic complex.
Gao C; Dimitrov T; Yong KJ; Tatetsu H; Jeong HW; Luo HR; Bradner JE; Tenen DG; Chai L
Blood; 2013 Feb; 121(8):1413-21. PubMed ID: 23287862
[TBL] [Abstract][Full Text] [Related]
16. Targeting an Inducible SALL4-Mediated Cancer Vulnerability with Sequential Therapy.
Yang J; Gao C; Liu M; Liu YC; Kwon J; Qi J; Tian X; Stein A; Liu YV; Kong NR; Wu Y; Yin S; Xi J; Chen Z; Kumari K; Wong H; Luo H; Silberstein LE; Thoms JAI; Unnikrishnan A; Pimanda JE; Tenen DG; Chai L
Cancer Res; 2021 Dec; 81(23):6018-6028. PubMed ID: 34593523
[TBL] [Abstract][Full Text] [Related]
17. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
[TBL] [Abstract][Full Text] [Related]
18. Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
Gupta VG; Hirst J; Petersen S; Roby KF; Kusch M; Zhou H; Clive ML; Jewell A; Pathak HB; Godwin AK; Wilson AJ; Crispens MA; Cybulla E; Vindigni A; Fuh KC; Khabele D
Gynecol Oncol; 2021 Jul; 162(1):163-172. PubMed ID: 33867143
[TBL] [Abstract][Full Text] [Related]
19. The HDAC3-SMARCA4-miR-27a axis promotes expression of the
Bharathy N; Berlow NE; Wang E; Abraham J; Settelmeyer TP; Hooper JE; Svalina MN; Ishikawa Y; Zientek K; Bajwa Z; Goros MW; Hernandez BS; Wolff JE; Rudek MA; Xu L; Anders NM; Pal R; Harrold AP; Davies AM; Ashok A; Bushby D; Mancini M; Noakes C; Goodwin NC; Ordentlich P; Keck J; Hawkins DS; Rudzinski ER; Chatterjee B; Bächinger HP; Barr FG; Liddle J; Garcia BA; Mansoor A; Perkins TJ; Vakoc CR; Michalek JE; Keller C
Sci Signal; 2018 Nov; 11(557):. PubMed ID: 30459282
[TBL] [Abstract][Full Text] [Related]
20. The multi-kinase inhibitor lenvatinib interacts with the HDAC inhibitor entinostat to kill liver cancer cells.
Roberts JL; Poklepovic A; Booth L; Dent P
Cell Signal; 2020 Jun; 70():109573. PubMed ID: 32087304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]